# Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer

> **NCT02980965** · PHASE3 · COMPLETED · sponsor: **Fudan University** · enrollment: 249 (actual)

## Conditions studied

- Breast Cancer Female

## Interventions

- **DRUG:** letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel
- **DRUG:** fluorouracil, epirubicin, cyclophosphamide, docetaxel

## Key facts

- **NCT ID:** NCT02980965
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 249 (ACTUAL)
- **Last updated:** 2017-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02980965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02980965, "Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02980965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*